Skip to main navigation Products Investors News Careers Contact SIGA: Human BioArmor MENU Press Release Details SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021 September 7, 2021 at 1:16 PM EDT PDF Version NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company’s Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltimore, Maryland. Dr. Gomez will be giving a presentation "Antiviral Drugs: Adapting Capabilities for an Effective Response to Future Epidemic Outbreaks" and will join a panel with leadership from Health and Human Services and the Department of Defense to discuss future pandemic preparedness. "As we begin to understand the lessons learned from COVID-19, we are reminded that antiviral drugs are challenging to develop, but critical to any pandemic preparedness plan," said Dr. Gomez. "TPOXX® is an incredible case study in development and deployment of an antiviral drug for smallpox, and we are working to expand regulatory approvals for additional orthropox viruses and post-exposure prophylactic use. Preparedness is more efficient and saves lives relative to response, and robust stockpiling of products like TPOXX is important to ensure outbreaks do not rapidly spiral out of control. I look forward to discussing these lessons learned and future preparedness opportunities at the NCT USA conference," Dr. Gomez noted. ABOUT SIGA TECHNOLOGIES, INC. and TPOXX® SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX® is a novel small-molecule drug and the U.S. Government maintains a stockpile of TPOXX for treatment of smallpox. Over the past decade, the U.S. Government has procured, or has current orders for, approximately $705 million of TPOXX for such stockpile. Under the current procurement contract with the U.S. Government, there are approximately $300 million of procurement-related options for oral and IV TPOXX remaining for future exercise. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253. For more information about SIGA, please visit www.siga.com. About Smallpox1 Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus. COVID-19 Pandemic The COVID-19 pandemic has caused significant societal and economic disruption. Such disruption, and the associated risks and costs, are expected to continue for an indeterminate period of time. Given the uncertain scale, scope, and current and future impact of the pandemic, the Company is regularly reviewing business and financial risks, and seeking coordination with its government partners with respect to the performance of current and future contract timing and execution. Additionally, the Company is coordinating closely with service providers and vendors, in particular contract manufacturing organizations that constitute our supply chain, with respect to actions and risks caused by the COVID-19 pandemic. Finally, the Company has proactively provided its employees with resources and other support to help ensure continued success in remote work settings as they navigate the current pandemic environment. The COVID-19 pandemic has not adversely affected the liquidity position of the Company, nor is it currently expected to have a material adverse effect on the financial condition of the Company. The pandemic has and may continue to delay the timing of international contract awards for oral TPOXX® given the need of government officials to focus on meeting the demands of the current COVID-19 pandemic. Additionally, the pandemic could result in a slower pace of product deliveries if the pandemic results in shortages or delays in the receipt by the supply chain of raw materials and other essential items for manufacturing. Otherwise, the pandemic is not currently expected to have a material adverse effect on the short-term financial results of the Company, although the Company cannot provide assurances as to the ultimate impact of the pandemic upon the broader macro environment or the Company’s industry. FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the year ended December 31, 2020, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise. The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred. Investor Contacts: Laine Yonker, Edison Group lyonker@edisongroup.com Michael Crawford, Edison Group mcrawford@edisongroup.com 1 http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769 Source: SIGA Technologies Inc. Latest Press Releases Nov 16, 2021 European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Nov 04, 2021 SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Oct 28, 2021 SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results Shareholder Tools Print Email Alerts RSS News Feeds Contact IR SIGA: Human BioArmor Corporate Headquarters 31 East 62nd Street New York, NY 10065 (212) 672-9100 SIGA Development Operations 4575 SW Research Way, Suite 110 Corvallis, OR 97333 (541) 753-2000 Privacy Notice © 2021 SIGA Technologies, All Rights Reserved By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies